American Association for the Advancement of Science, Science Translational Medicine, 624(13), 2021
DOI: 10.1126/scitranslmed.abj5070
Full text: Unavailable
A phase 1/2 clinical trial in patients with chemoresistant triple-negative breast cancer targets the inducible nitric oxide signaling pathway.